Able to provide voluntary, written informed consent with comprehension of all aspects of the protocol, prior to any study procedures. 
Healthy obese male and female volunteers aged 18 to 55 years, inclusive. Heterozygous subjects may be 18 to 65 years inclusive. 
In good general health, without significant medical history, physical examination findings, or clinical laboratory abnormalities. 
Body Mass Index of 30-40 kg/m2, inclusive. Heterozygous subjects may have a broader BMI range; to be eligible heterozygous subjects may have a BMI 27 -55 kg/ m2, inclusive. 
Stable body weight during the previous 6 months, based on Investigator judgment. 
Blood pressure <140/90 mmHg at Screening and D-1. Measurement may be repeated within 24 hours, based on Investigator judgment. 
Females must not be pregnant and must have a negative serum pregnancy test result at the Screening Visit and Day -1. 
Females of childbearing potential must agree to be abstinent or else use any two of the following medically acceptable forms of contraception from the Screening Period through the Final Study Visit: hormonal, condom with spermicidal jelly, diaphragm or cervical cap with spermicidal jelly, or IUD. Hormonal contraception must have started at least 3 months prior to screening. A female whose male partner has had a vasectomy must agree to use one additional form of medically acceptable contraception. Subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution. 
Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months (and confirmed with a screening FSH level in the post-menopausal range), do not require contraception during the study. 
Males with female partners of childbearing potential must agree to use two medically acceptable forms of contraception as described above, with one of the two forms being condom with spermicide, from the Screening Period through the Final Study Visit. Males with female partners of childbearing potential who themselves are surgically sterile (status post vasectomy) must agree to use condoms with spermicide over the same period of time. Male subjects must agree to practice the above birth control methods for 30 days from the final visit as a safety precaution. 

NCT02431442_inc_T3
Condition
obese
NCT02431442_inc_T4
Condition
Healthy
NCT02431442_inc_T5
Person
male
NCT02431442_inc_T6
Person
female
NCT02431442_inc_T8
Person
aged
NCT02431442_inc_T9
Value
18 to 55 years, inclusive
NCT02431442_inc_T10
Condition
Heterozygous
NCT02431442_inc_T12
Value
18 to 65 years inclusive
NCT02431442_inc_T14
Condition
good general health
NCT02431442_inc_T18
Measurement
Body Mass Index
NCT02431442_inc_T19
Value
30-40 kg/m2, inclusive
NCT02431442_inc_T20
Condition
Heterozygous
NCT02431442_inc_T22
Condition
heterozygous
NCT02431442_inc_T23
Measurement
BMI
NCT02431442_inc_T24
Value
27 -55 kg/ m2, inclusive
NCT02431442_inc_T26
Measurement
body weight
NCT02431442_inc_T27
Qualifier
Stable
NCT02431442_inc_T28
Temporal
during the previous 6 months
NCT02431442_inc_T30
Measurement
Blood pressure
NCT02431442_inc_T31
Value
<140/90 mmHg
NCT02431442_inc_T32
Temporal
at Screening and D-1
NCT02431442_inc_T33
Reference_point
Screening and D-1
NCT02431442_inc_T37
Condition
pregnant
NCT02431442_inc_T38
Negation
not
NCT02431442_inc_T39
Person
Females
NCT02431442_inc_T40
Measurement
serum pregnancy test
NCT02431442_inc_T41
Value
negative
NCT02431442_inc_T42
Temporal
at the Screening Visit and Day -1
NCT02431442_inc_T43
Reference_point
the Screening Visit and Day -1
NCT02431442_inc_T45
Condition
childbearing potential
NCT02431442_inc_T48
Procedure
Hormonal contraception
NCT02431442_inc_T49
Temporal
at least 3 months prior to screening
NCT02431442_inc_T50
Reference_point
screening